Interview with Howard Sui, Managing Director, Merck Serono China
As growth has stalled in Europe, the US and Japan, many multinational companies are looking at China as part of a hedging strategy and a key growth driver of the…
Address: 10F, Tower B, Gemdal Plaza,
No.91 Jianguo Road,
Chaoyang District,
100022 Beijing,
P.R. China
Tel: +86-10-5907-2688
Web: http://www.merck-china.com/en/pharmaceuticals/pharmaceuticals.html
Merck Group in China is the sales organization of the globally operating group Merck KGaA, Darmstadt (Germany) and provides the Chinese market with high-quality pharmaceutical and chemical products. In fact, Merck initiated its business in China as early as 1900. One hundred years later, Merck is represented in the most developed cities in China, including Hong Kong.
Cardiovascular, thyroid, surgical, growth hormone and anti-allergy, women’s health and fertility, neurodegenerative diseases and oncology
As growth has stalled in Europe, the US and Japan, many multinational companies are looking at China as part of a hedging strategy and a key growth driver of the…
While China may be grappling with an economic slowdown and escalating geopolitical tensions, it remains the world’s second largest pharma market and a country that boasts an extraordinarily dynamic life…
Beyond political, cultural, economic, and linguistic concerns, the sheer pace of Chinese pharma’s development makes it challenging for international observers to fully grasp the sector’s intricacies, challenges, and numerous opportunities.…
2024 marks 30 years for Takeda in China, and the company has been outstripping the overall market to grow by double-digits in the country since 2020. Sean Shan discusses how…
Shawn Leung, CEO of Chinese biotech SinoMab, discusses the”Biotech 3.0″ philosophy that characterizes the company as it strives for both scientific innovation and differentiation. He highlights SinoMab’s atopic dermatitis and…
Dr Yingjia Zhang and Simon Hua of leading China-based CRO Biometas delve into the company’s rapid expansion in the preclinical space, strategic growth plans, and its positioning in the global…
Jens Ewert, Life Science and Health Care Industry Leader at Deloitte China, provides an in-depth analysis of the development of China’s healthcare landscape over the previous past four years. Ewert…
Deng Haoqing, President and General Manager of Chiesi China, explores the company’s strategic growth in one of the world’s most dynamic healthcare markets. Deng discusses the alignment of Chiesi’s “AIR,…
Jun Liu, CEO & Executive Board Director of BioDlink, defines and explores the company’s strategic focus on antibody drug conjugates (ADCs), their global expansion plans, and role as a leading…
Vivian Zhang, Managing Director and General Manager of Merck China Healthcare, shares insights into the market’s strategic importance to the company and its current priorities in the country. She discusses…
EpimAb Biotherapeutics’ Chengbin Wu explains why the expansion of bispecifics into solid tumors and autoimmune diseases marks a major therapeutic turning point. He outlines how, through rational antibody engineering and…
A roundup of some of the biggest stories coming out of China’s pharma industry, including the new drugs added to the country’s national health insurance with AstraZeneca’s breast cancer blockbuster,…
Vincent Chan, VP and GM of bioMérieux Greater China, shares insights into how the microbiology diagnostics company’s presence has evolved in China over the course of 30 years to today…
See our Cookie Privacy Policy Here
